| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 22 | 2022 | 124 | 2.120 |
Why?
|
| Angioplasty, Balloon, Coronary | 18 | 2022 | 39 | 2.010 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2022 | 8 | 1.380 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2022 | 20 | 1.230 |
Why?
|
| Stem Cell Transplantation | 6 | 2018 | 37 | 1.170 |
Why?
|
| Coronary Restenosis | 5 | 2015 | 10 | 1.060 |
Why?
|
| Stents | 11 | 2004 | 75 | 0.950 |
Why?
|
| Antigens, CD34 | 6 | 2018 | 12 | 0.880 |
Why?
|
| Angina Pectoris | 6 | 2018 | 16 | 0.790 |
Why?
|
| Cicatrix | 1 | 2022 | 7 | 0.750 |
Why?
|
| Nanoparticles | 1 | 2022 | 10 | 0.750 |
Why?
|
| Electrocardiography | 7 | 2015 | 92 | 0.730 |
Why?
|
| Coronary Angiography | 10 | 2022 | 68 | 0.730 |
Why?
|
| No-Reflow Phenomenon | 1 | 2022 | 1 | 0.720 |
Why?
|
| Cardiac Catheterization | 5 | 2017 | 55 | 0.700 |
Why?
|
| Brachytherapy | 5 | 2004 | 44 | 0.690 |
Why?
|
| Myocardial Ischemia | 3 | 2017 | 44 | 0.650 |
Why?
|
| Myocardium | 10 | 2018 | 101 | 0.630 |
Why?
|
| Humans | 58 | 2022 | 23495 | 0.560 |
Why?
|
| MicroRNAs | 2 | 2015 | 38 | 0.550 |
Why?
|
| Coronary Artery Disease | 6 | 2016 | 124 | 0.530 |
Why?
|
| Triage | 2 | 2015 | 18 | 0.530 |
Why?
|
| Drug-Eluting Stents | 2 | 2015 | 14 | 0.520 |
Why?
|
| Stem Cells | 4 | 2022 | 35 | 0.520 |
Why?
|
| Heart Injuries | 1 | 2017 | 1 | 0.520 |
Why?
|
| Body Surface Potential Mapping | 1 | 2017 | 2 | 0.520 |
Why?
|
| Heart Aneurysm | 1 | 2017 | 6 | 0.520 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 5 | 0.500 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2004 | 19 | 0.490 |
Why?
|
| Heart Ventricles | 1 | 2017 | 81 | 0.490 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2016 | 12 | 0.480 |
Why?
|
| Emergency Service, Hospital | 4 | 2015 | 255 | 0.470 |
Why?
|
| Vascular Remodeling | 1 | 2015 | 4 | 0.450 |
Why?
|
| Vascular System Injuries | 1 | 2015 | 4 | 0.450 |
Why?
|
| Genetic Therapy | 3 | 2013 | 83 | 0.440 |
Why?
|
| Animals | 15 | 2022 | 3321 | 0.430 |
Why?
|
| Catheters | 2 | 2021 | 15 | 0.420 |
Why?
|
| Early Diagnosis | 1 | 2014 | 51 | 0.420 |
Why?
|
| Inpatients | 1 | 2014 | 113 | 0.390 |
Why?
|
| Middle Aged | 35 | 2018 | 8096 | 0.390 |
Why?
|
| Male | 42 | 2018 | 12823 | 0.380 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 10 | 0.380 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2016 | 30 | 0.380 |
Why?
|
| Needles | 1 | 2012 | 17 | 0.380 |
Why?
|
| Treatment Outcome | 23 | 2021 | 3058 | 0.370 |
Why?
|
| Ventricular Function, Left | 6 | 2016 | 34 | 0.370 |
Why?
|
| Neovascularization, Physiologic | 3 | 2016 | 23 | 0.360 |
Why?
|
| Heart Failure | 5 | 2016 | 141 | 0.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 106 | 0.340 |
Why?
|
| Myocardial Revascularization | 4 | 2004 | 16 | 0.340 |
Why?
|
| Strontium Radioisotopes | 4 | 2003 | 8 | 0.330 |
Why?
|
| Coronary Disease | 6 | 2003 | 49 | 0.330 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2016 | 40 | 0.330 |
Why?
|
| Aged | 29 | 2018 | 7709 | 0.330 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 3 | 0.320 |
Why?
|
| Female | 34 | 2018 | 13305 | 0.320 |
Why?
|
| Time Factors | 11 | 2016 | 1276 | 0.310 |
Why?
|
| Coronary Stenosis | 3 | 2004 | 16 | 0.310 |
Why?
|
| Beta Particles | 4 | 2003 | 7 | 0.290 |
Why?
|
| Follow-Up Studies | 14 | 2015 | 1492 | 0.280 |
Why?
|
| Poloxalene | 4 | 1996 | 4 | 0.270 |
Why?
|
| Transplantation, Autologous | 6 | 2018 | 103 | 0.270 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2016 | 7 | 0.260 |
Why?
|
| Laser Therapy | 2 | 2004 | 11 | 0.250 |
Why?
|
| Gastric Fundus | 1 | 2006 | 2 | 0.250 |
Why?
|
| Gastric Fistula | 1 | 2006 | 5 | 0.250 |
Why?
|
| Electrodes | 1 | 2006 | 13 | 0.250 |
Why?
|
| Pericardium | 1 | 2006 | 20 | 0.250 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 10 | 0.250 |
Why?
|
| Double-Blind Method | 11 | 2016 | 374 | 0.240 |
Why?
|
| Myocardial Reperfusion | 3 | 1996 | 5 | 0.230 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 1995 | 6 | 0.220 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2004 | 1 | 0.210 |
Why?
|
| Integrin beta3 | 1 | 2004 | 3 | 0.210 |
Why?
|
| Myocardial Stunning | 1 | 2004 | 2 | 0.210 |
Why?
|
| Heart Transplantation | 1 | 2004 | 29 | 0.210 |
Why?
|
| Blood Platelets | 1 | 2004 | 35 | 0.210 |
Why?
|
| Embolism, Cholesterol | 1 | 2004 | 1 | 0.210 |
Why?
|
| Vascular Diseases | 1 | 2004 | 34 | 0.210 |
Why?
|
| Echocardiography | 3 | 2017 | 68 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 70 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 95 | 0.190 |
Why?
|
| Exercise Tolerance | 3 | 2018 | 30 | 0.190 |
Why?
|
| Coronary Circulation | 6 | 1996 | 27 | 0.190 |
Why?
|
| Receptors, Fc | 1 | 2022 | 5 | 0.190 |
Why?
|
| Complement Activation | 1 | 2022 | 7 | 0.190 |
Why?
|
| Epitopes | 1 | 2022 | 38 | 0.190 |
Why?
|
| Blood Substitutes | 3 | 1995 | 3 | 0.180 |
Why?
|
| Fluorocarbons | 3 | 1995 | 11 | 0.180 |
Why?
|
| Visual Perception | 1 | 2002 | 21 | 0.180 |
Why?
|
| Echocardiography, Doppler | 2 | 2001 | 16 | 0.180 |
Why?
|
| Macrophages | 1 | 2022 | 79 | 0.180 |
Why?
|
| Heart | 2 | 1994 | 59 | 0.180 |
Why?
|
| Prospective Studies | 13 | 2016 | 1528 | 0.180 |
Why?
|
| Wound Healing | 1 | 2022 | 118 | 0.180 |
Why?
|
| Hemodynamics | 5 | 2001 | 54 | 0.180 |
Why?
|
| Atherectomy, Coronary | 1 | 2021 | 2 | 0.180 |
Why?
|
| Mammary Arteries | 1 | 2021 | 8 | 0.170 |
Why?
|
| Cytokines | 1 | 2022 | 193 | 0.170 |
Why?
|
| Mice | 2 | 2022 | 1264 | 0.160 |
Why?
|
| Thrombolytic Therapy | 2 | 2002 | 44 | 0.160 |
Why?
|
| Swine | 2 | 2012 | 68 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2016 | 3082 | 0.150 |
Why?
|
| Dogs | 8 | 1996 | 136 | 0.140 |
Why?
|
| Marital Status | 1 | 2018 | 9 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 192 | 0.140 |
Why?
|
| Angioplasty, Balloon | 5 | 2004 | 14 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 250 | 0.140 |
Why?
|
| Mortality | 1 | 2018 | 76 | 0.130 |
Why?
|
| Injections, Intramuscular | 2 | 2018 | 8 | 0.130 |
Why?
|
| Radionuclide Ventriculography | 1 | 2017 | 1 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 309 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2016 | 19 | 0.120 |
Why?
|
| Cardiology | 2 | 2016 | 45 | 0.120 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2016 | 1 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2004 | 20 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 25 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 162 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 29 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2004 | 807 | 0.120 |
Why?
|
| Blood Cells | 1 | 2015 | 3 | 0.110 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2015 | 8 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 6 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1995 | 21 | 0.110 |
Why?
|
| Hospital Design and Construction | 1 | 2015 | 5 | 0.110 |
Why?
|
| Stroke Volume | 4 | 2002 | 41 | 0.110 |
Why?
|
| Shock, Septic | 3 | 1990 | 25 | 0.110 |
Why?
|
| Equipment Design | 3 | 2012 | 128 | 0.110 |
Why?
|
| Patient Transfer | 1 | 2014 | 24 | 0.110 |
Why?
|
| Atherosclerosis | 1 | 2015 | 47 | 0.110 |
Why?
|
| Gene Transfer Techniques | 2 | 2005 | 29 | 0.100 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2016 | 27 | 0.100 |
Why?
|
| Biomarkers | 2 | 2016 | 486 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2014 | 80 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2003 | 445 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2006 | 594 | 0.100 |
Why?
|
| Survival Rate | 3 | 2004 | 320 | 0.100 |
Why?
|
| Fibrinolytic Agents | 4 | 2010 | 58 | 0.100 |
Why?
|
| Angina, Stable | 1 | 2013 | 2 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 9 | 0.100 |
Why?
|
| Plasmids | 1 | 2013 | 42 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2003 | 130 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 11 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 69 | 0.090 |
Why?
|
| Fluoroscopy | 1 | 2012 | 35 | 0.090 |
Why?
|
| Radiography | 2 | 2004 | 547 | 0.090 |
Why?
|
| Cell Survival | 1 | 2012 | 100 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 103 | 0.090 |
Why?
|
| Length of Stay | 1 | 2014 | 298 | 0.090 |
Why?
|
| Exercise Test | 3 | 2016 | 112 | 0.090 |
Why?
|
| Early Medical Intervention | 1 | 2012 | 13 | 0.090 |
Why?
|
| Recurrence | 2 | 2003 | 272 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 340 | 0.090 |
Why?
|
| Combined Modality Therapy | 5 | 2004 | 295 | 0.090 |
Why?
|
| Adult | 12 | 2016 | 7090 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2012 | 110 | 0.080 |
Why?
|
| Cocaine | 1 | 1990 | 31 | 0.080 |
Why?
|
| Acute Kidney Injury | 2 | 1990 | 34 | 0.080 |
Why?
|
| Registries | 2 | 2010 | 180 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 7 | 0.080 |
Why?
|
| Dinoprostone | 1 | 1990 | 16 | 0.080 |
Why?
|
| Sirolimus | 1 | 2010 | 20 | 0.080 |
Why?
|
| Renal Circulation | 2 | 1990 | 4 | 0.080 |
Why?
|
| Thoracotomy | 2 | 2006 | 30 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2004 | 533 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 115 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 907 | 0.070 |
Why?
|
| Coronary Vessels | 3 | 2016 | 33 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2005 | 14 | 0.070 |
Why?
|
| Injections | 3 | 2013 | 42 | 0.070 |
Why?
|
| Stroke | 2 | 2016 | 243 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2004 | 236 | 0.070 |
Why?
|
| Collateral Circulation | 3 | 1999 | 4 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2004 | 552 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2004 | 369 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 24 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2006 | 35 | 0.060 |
Why?
|
| Foreign-Body Migration | 1 | 2006 | 18 | 0.060 |
Why?
|
| Device Removal | 1 | 2006 | 68 | 0.060 |
Why?
|
| United States | 4 | 2016 | 1814 | 0.060 |
Why?
|
| Tryptamines | 1 | 2005 | 1 | 0.060 |
Why?
|
| Oxazolidinones | 1 | 2005 | 2 | 0.060 |
Why?
|
| Norepinephrine | 1 | 1985 | 28 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2005 | 18 | 0.060 |
Why?
|
| Dopamine | 1 | 1985 | 77 | 0.050 |
Why?
|
| Angiography | 2 | 2003 | 25 | 0.050 |
Why?
|
| Vascular Resistance | 3 | 1990 | 12 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 2026 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 48 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 6 | 0.050 |
Why?
|
| Neutrophils | 2 | 1995 | 89 | 0.050 |
Why?
|
| Extremities | 1 | 2004 | 24 | 0.050 |
Why?
|
| Ischemia | 1 | 2004 | 21 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2004 | 17 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 12 | 0.050 |
Why?
|
| Calcinosis | 1 | 2004 | 43 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2004 | 35 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2004 | 4 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 164 | 0.050 |
Why?
|
| Iodine Compounds | 1 | 2003 | 1 | 0.050 |
Why?
|
| Fenoldopam | 1 | 2003 | 1 | 0.050 |
Why?
|
| Dopamine Agonists | 1 | 2003 | 15 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2004 | 89 | 0.050 |
Why?
|
| Hematologic Agents | 1 | 2003 | 3 | 0.050 |
Why?
|
| Angina, Unstable | 1 | 2003 | 9 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 28 | 0.050 |
Why?
|
| Lymphokines | 1 | 2003 | 10 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2003 | 11 | 0.050 |
Why?
|
| Saphenous Vein | 1 | 2003 | 5 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2004 | 61 | 0.050 |
Why?
|
| Contrast Media | 1 | 2003 | 60 | 0.050 |
Why?
|
| Rhodotorula | 1 | 2003 | 1 | 0.050 |
Why?
|
| DNA | 1 | 2003 | 99 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2003 | 12 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2003 | 22 | 0.050 |
Why?
|
| Incidence | 2 | 2003 | 642 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2003 | 11 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 3874 | 0.050 |
Why?
|
| Mycoses | 1 | 2003 | 17 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 45 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 85 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2003 | 69 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2003 | 57 | 0.050 |
Why?
|
| Necrosis | 2 | 1994 | 22 | 0.050 |
Why?
|
| Death | 1 | 2003 | 40 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 198 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2002 | 15 | 0.050 |
Why?
|
| Illinois | 1 | 2003 | 225 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 297 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 121 | 0.050 |
Why?
|
| Reoperation | 2 | 2003 | 767 | 0.040 |
Why?
|
| Diastole | 1 | 2001 | 28 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 315 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2004 | 827 | 0.040 |
Why?
|
| Surface-Active Agents | 2 | 1999 | 5 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 1999 | 11 | 0.040 |
Why?
|
| Quality of Life | 2 | 2016 | 570 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 608 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 168 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cardiovascular Agents | 2 | 2012 | 22 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 1996 | 3 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2016 | 1 | 0.030 |
Why?
|
| Blood Pressure | 2 | 1990 | 171 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 1 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1997 | 99 | 0.030 |
Why?
|
| Placebos | 1 | 1996 | 63 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2016 | 5 | 0.030 |
Why?
|
| Radial Artery | 1 | 2016 | 6 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1996 | 33 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 162 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 166 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2016 | 73 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 124 | 0.030 |
Why?
|
| Clinical Competence | 1 | 1997 | 191 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 254 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1994 | 11 | 0.030 |
Why?
|
| Gases | 1 | 1994 | 5 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2014 | 14 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2014 | 22 | 0.030 |
Why?
|
| Ventricular Fibrillation | 1 | 1994 | 13 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 48 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 314 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 28 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 41 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 283 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2015 | 468 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 368 | 0.030 |
Why?
|
| Rats | 1 | 2015 | 625 | 0.030 |
Why?
|
| Lactates | 2 | 1990 | 4 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 2 | 1990 | 35 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 8 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2003 | 6 | 0.020 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 1992 | 1 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 59 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 75 | 0.020 |
Why?
|
| Logistic Models | 2 | 2004 | 357 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 10 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2012 | 19 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 53 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2012 | 56 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 98 | 0.020 |
Why?
|
| Phentolamine | 1 | 1990 | 1 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2002 | 227 | 0.020 |
Why?
|
| Propranolol | 1 | 1990 | 4 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1990 | 14 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2012 | 129 | 0.020 |
Why?
|
| Creatinine | 2 | 2003 | 41 | 0.020 |
Why?
|
| Thermodilution | 1 | 1990 | 4 | 0.020 |
Why?
|
| Renal Veins | 1 | 1990 | 2 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2010 | 6 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 16 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 25 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 1990 | 25 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 1990 | 25 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 1989 | 5 | 0.020 |
Why?
|
| Prednisone | 1 | 1989 | 63 | 0.020 |
Why?
|
| Kidney | 1 | 1990 | 142 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 1500 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 1724 | 0.020 |
Why?
|
| Streptokinase | 1 | 1987 | 1 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 10 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1985 | 12 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1985 | 31 | 0.010 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2005 | 3 | 0.010 |
Why?
|
| Heart Rate | 1 | 1985 | 104 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 126 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2003 | 3 | 0.010 |
Why?
|
| Factor Xa Inhibitors | 1 | 2003 | 4 | 0.010 |
Why?
|
| Dipeptides | 1 | 1983 | 3 | 0.010 |
Why?
|
| Aortic Valve | 1 | 2003 | 22 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1983 | 21 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2003 | 35 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 35 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 210 | 0.010 |
Why?
|
| Radionuclide Angiography | 1 | 2002 | 1 | 0.010 |
Why?
|
| Manometry | 1 | 2001 | 15 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 103 | 0.010 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2001 | 5 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 75 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2000 | 24 | 0.010 |
Why?
|
| Poloxamer | 1 | 1999 | 3 | 0.010 |
Why?
|
| Computer Systems | 1 | 1999 | 7 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 41 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 737 | 0.010 |
Why?
|
| American Heart Association | 1 | 1998 | 15 | 0.010 |
Why?
|
| Credentialing | 1 | 1997 | 5 | 0.010 |
Why?
|
| Societies, Medical | 1 | 1998 | 118 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 1997 | 24 | 0.010 |
Why?
|
| Health Services Research | 1 | 1997 | 29 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 1997 | 34 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1997 | 232 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 1997 | 130 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 167 | 0.010 |
Why?
|
| Chicago | 1 | 1997 | 848 | 0.010 |
Why?
|
| Catecholamines | 1 | 1990 | 7 | 0.010 |
Why?
|
| Calibration | 1 | 1990 | 18 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1990 | 21 | 0.010 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1990 | 55 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1989 | 50 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1989 | 51 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1989 | 155 | 0.000 |
Why?
|
| Staphylococcal Infections | 1 | 1990 | 155 | 0.000 |
Why?
|
| Anemia, Aplastic | 1 | 1986 | 1 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1986 | 8 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1986 | 52 | 0.000 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 42 | 0.000 |
Why?
|
| Neoplasms | 1 | 1986 | 220 | 0.000 |
Why?
|
| Enalapril | 1 | 1983 | 1 | 0.000 |
Why?
|
| Saralasin | 1 | 1983 | 1 | 0.000 |
Why?
|
| Teprotide | 1 | 1983 | 1 | 0.000 |
Why?
|
| Hypotension, Orthostatic | 1 | 1983 | 10 | 0.000 |
Why?
|
| Long-Term Care | 1 | 1983 | 56 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1983 | 96 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1983 | 378 | 0.000 |
Why?
|
| Adolescent | 1 | 1986 | 1911 | 0.000 |
Why?
|